|
| Press Releases |
|
 |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China |
| China Medical System Holdings Limited ("CMS", or the "Group") is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the "Product") has been approved for marketing in China by the National Medical Products Administration of the People's Republic of China (NMPA). more info >> |
|
| Monday, December 15, 2025 |
|
|
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China |
| more info >> |
|
| Thursday, December 11, 2025 |
|
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) ("Y-3 for Injection" or the "Product") has been accepted by National Medical Products Administration of the People's Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. more info >> |
|
| Thursday, October 30, 2025 |
|
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection ("MG-K10" or the "Product"). more info >> |
|
| Monday, October 27, 2025 |
|
|
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) |
| more info >> |
|
| Sunday, September 28, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the "Trial") of ruxolitinib cream (the "Product") in patients with mild to moderate atopic dermatitis (AD) in China. more info >> |
|
| Tuesday, September 23, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
| Tuesday, August 19, 2025 |
|
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
| On 18 August, China Medical System Holdings Limited ("CMS" or the "Company") announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. more info >> |
|
| Tuesday, July 29, 2025 |
|
|
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) ("ZUNVEYL" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 22, 2025 |
|
|
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets |
| On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited ("CMS" or the "Group") on the Main Board of the Singapore Exchange ("SGX"), SGX and CMS co-hosted the "Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner". more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY
Mar 24, 2026 10:31 HKT/SGT
|
|
|
International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study
Mar 24, 2026 07:29 HKT/SGT
|
|
|
Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion
Mar 24, 2026 04:59 HKT/SGT
|
|
|
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries
Mar 23, 2026 23:15 HKT/SGT
|
|
|
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Mar 23, 2026 21:05 HKT/SGT
|
|
|
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share
Mar 23, 2026 20:51 HKT/SGT
|
|
|
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe
Mar 23, 2026 20:29 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 23, 2026 18:59 HKT/SGT
|
|
|
From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas
Mar 23, 2026 14:15 HKT/SGT
|
|
|
Fujitsu-developed traffic simulation system utilized in Maebashi City's public transportation planning
Mar 23, 2026 14:24 JST
|
|
|
Hitachi Receives the 2026 Catalyst Award, a Global Recognition for Building an Inclusive Organization
Mar 23, 2026 11:49 JST
|
|
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 23, 2026 11:19 JST
|
|
|
Unitree Robotics IPO Ignites Embodied-Intelligence Rally, Shoucheng Holdings (0697.HK) Faces a Dual Catalyst of 'Investment Realisation+Platform Re-Rating'
Mar 23, 2026 08:22 HKT/SGT
|
|
|
AEM and ASE Enter Strategic Partnership to Accelerate AI and HPC Test Innovation
Mar 23, 2026 08:00 HKT/SGT
|
|
|
FILMART and EntertainmentPulse draw about 8,000 industry participants
Mar 20, 2026 20:40 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
